Immunocore Holdings plc IMCR
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -13.48%
- 1 year
- -7.26%
- Market cap
- 1.55B
- Revenue (ttm)
- 430.78M
- Profit margin
- -4.20%
- EPS (ttm)
- -0.36
- Shares out
- 51.50M
- Forward P/E
- -38.78
- YTD return
- -13.48%
- 1-year return
- -7.26%
- Volume
- 252.84K
- Avg volume
- 435.30K
- Open
- 29.83
- Previous close
- 29.79
- Day's range
- 29.83 – 30.95
- 52-week range
- 27.50 – 40.72
- Beta
- 0.81
- Analysts
- Buy
- Price target
- 62.73 (+108.9%)
- Earnings date
- Nov 5, 2026
2Y -1.14 (-3.66%)
Key statistics
- Enterprise value
- 1.09B
- PEG ratio
- 0.00
- Price / sales
- 3.59
- Price / book
- 3.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 18.30%
- Free cash flow
- 35.59M
- Total cash
- 880.21M
- Total debt
- 434.96M
- Return on equity
- -4.47%
- Short % of float
- 16.83%
- 50-day average
- 32.22
- 200-day average
- 31.75
Analyst view
Consensus: buy
- Target (low)
- 34.00
- Target (mean)
- 62.73
- Target (high)
- 100.00
- Strong buy2
- Buy7
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.13045.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.17491 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.01 | -0.02 | -0.01 | -100.00% |
| May 6, 2026 | Mar 31, 2026 | -0.26 | 0.25 | +0.51 | +196.15% |
| Feb 25, 2026 | Dec 31, 2025 | -0.28 | -0.60 | -0.32 | -114.29% |
| Nov 6, 2025 | Sep 30, 2025 | -0.30 | 0.01557 | +0.32 | +105.19% |
| Aug 7, 2025 | Jun 30, 2025 | -0.21 | -0.20 | +0.01 | +4.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 3, 2026 | Mizuho | main | Neutral | Neutral |
| Apr 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 16, 2026 | Jefferies | down | Buy | Hold |
| Feb 26, 2026 | Needham | main | Buy | Buy |
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- immunocore.com
News
Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting 
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting 
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target 
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes 
Immunocore Hldgs Q2 2026 Earnings Call Transcript 
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study 
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript - Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma 
Immunocore to present at upcoming investor conferences
Your note
Sign in to keep a note on IMCR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Director | Purchase | Mar 16, 2025 | 0 |
| BERMAN DAVID M | Officer | Sale | Feb 17, 2026 | 5,859 |
| GOLL JOHN R | Officer | Sale | Feb 17, 2026 | 653 |
| JALLAL BAHIJA | Chief Executive Officer | Sale | Feb 17, 2026 | 12,343 |
| ST LEGER TINA AMBER | Officer | Sale | Feb 17, 2026 | 1,119 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 11.11% | 5,721,945 | 171.83M | Jun 29, 2026 |
| RTW Investments LP | 9.46% | 4,869,798 | 146.24M | Jun 29, 2026 |
| FMR, LLC | 8.36% | 4,307,246 | 129.35M | Jun 29, 2026 |
| Primecap Management Company | 7.06% | 3,638,241 | 109.26M | Jun 29, 2026 |
| Bellevue Group AG | 5.41% | 2,788,245 | 83.73M | Jun 29, 2026 |
| Tang Capital Management, LLC | 5.14% | 2,649,368 | 79.56M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 8.25% | 4,246,274 | 127.52M | Jul 30, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 4.54% | 2,335,650 | 70.14M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.16% | 1,111,200 | 33.37M | Jul 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.25% | 645,268 | 19.38M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.23% | 635,923 | 19.10M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.97% | 500,000 | 15.02M | Aug 30, 2026 |